Geron (GERN) Moves Higher Following ASH Presentation
Tweet
Share
E-mail
Geron Corp. (Nasdaq: GERN) shares are ticking higher early Tuesday morning following presentation by CEO John Scarlett at the ASH 2013 Analyst and Investor Event on Monday. The presentation was on preliminary results from Mayo Clinic investigator-sponsored trial (IST) of imetelstat in myelofibrosis.
The full set of presentation slides can be seen here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Atlassian (TEAM) comes ahead of Street estimates in Q1 but shares tumble
- Bristol-Myers Squibb (BMY) stock slips despite earnings beat
- Aligos Therapeutics Inc. (ALGS) Presents Positive Data from the ALG-097558 Phase 1 Study
Create E-mail Alert Related Categories
Conference Calls, Corporate News, FDA, Guidance, Management Comments, Momentum Movers, SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
